Business Context and Reporting Period
Company: Zentalis Pharmaceuticals, Inc. (ZNTL)
Filing Type: Form 8-K (Current Report)
Report Date: February 24, 2022
Reporting Period: Quarter and year ended December 31, 2021
This filing serves as a notification that the Company announced its financial results for the specified period. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
No material changes or comparative financial data are detailed in this filing text. The document solely references the announcement of results for the quarter and year ended December 31, 2021.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that a press release was issued on February 24, 2022, containing the full announcement. No specific guidance, outlook, or risk factors are detailed in this text.
Legal Status: The information in Item 2.02 and Exhibit 99.1 is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section unless expressly incorporated by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2021.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm if the "furnished" status of the financial data impacts its incorporation into future SEC filings.